Adagio Therapeutics

2 articles with Adagio Therapeutics

• Adagio Therapeutics to Participate in Cowen 41st Annual Health Care Conference

  2/22/2021

  Adagio Therapeutics, Inc., a biotechnology company developing best-in-class antibodies to broadly neutralize coronaviruses, today announced that Tillman Gerngross, Ph.D., chief executive officer, and Jane Henderson, chief financial officer, will participate in one-on-one investor meetings during the Cowen 41st Annual Health Care Conference on Monday, March 1, 2021.

• Adagio Therapeutics Announces Dosing of First Patient in Phase 1 Trial of ADG20, its Lead Monoclonal Antibody Candidate for the Treatment and Prevention of COVID-19

  2/16/2021

  -ADG20 is uniquely engineered to maximize potency, duration of effect, and ease of use in the community setting, and has shown outstanding manufacturability to meet global demand-